| Compounds | Topics | Title | Date |
|---|---|---|---|
| cannabis | ms in humans via article | In the cloud of cannabis: Caring for people with multiple sclerosis who use cannabis for symptom control | 2019 |
| Research to-date suggests a large proportion of people living with MS are using cannabis as a way to self-manage symptoms, and, if not, believe that there are potential benefits in using this drug | |||
| cannabis | ms,spasticity in humans via survey (n=29) | Cannabis Use in People with Multiple Sclerosis and Self-Reported Spasticity | Apr 2019 |
| Positive All subjects reported cannabis being somewhat or very helpful for pain and 78% (7/9) reported similar benefit for spasticity. | |||
| cannabis | ms,spasticity,pain in humans via placebo trial (n=30/37) | Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial | Jul 2012 |
|
Ingestion Method: inhaled 0.8g cigarette, 4% THC Positive Using an objective measure, we saw a beneficial effect of inhaled cannabis on spasticity among patients receiving insufficient relief from traditional treatments. Although generally well-tolerated, smoking cannabis had acute cognitive effects. | |||
| cannabis | ms,spasticity in humans via placebo trial (n=37/50) | Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. | Aug 2004 |
|
Ingestion Method: oral 2.5mg THC/0.9mg CBD Positive A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs. | |||
| THC,CBD | ms,neuropathy in humans via placebo trial (n=64) | Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. | Sep 2007 |
|
Ingestion Method: Sativex THC/CBD (27 mg/mL: 25 mg/mL) spray Positive THC/CBD was effective, with no evidence of tolerance, in these select patients with CNP and MS who completed approximately 2 years of treatment (n = 28). | |||
| CBD | ms in mice via experiment | Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. | Feb 2019 |
|
Ingestion Method: CBD-rich, ?9-THC low Cannabis indica subspecies (Avidekel) Our data show that CBD and purified Avidekel extracts are as efficient as Copaxone to alleviate the symptoms of proteolipid protein (PLP)-induced EAE in SJL/J mice. No synergistic effect was observed by combining CBD or Avidekel extracts with Copaxone. Our data support the use of Avidekel extracts in the treatment of MS symptoms. | |||
| cannabis | ms in humans via survey (n=2244/3606) | Illegal cannabis use is common among Danes with multiple sclerosis | May 2019 |
| Positive This study shows that illegal cannabis use is common among Danes with MS as only 21% of the current cannabis users received prescribed cannabis-based medicine. Current cannabis users reported high efficacy in relieving pain, spasticity and sleep disturbances. In addition, only mild to moderate severity of adverse effects were reported | |||
| cannabinoids | diabetes,ra,ms via review | Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand? | May 2019 |
|
Action Pathway: CB1,CB2 Thus, in this review, we summarize the mechanisms by which CBRs interact with the autoimmune environment and the potential to suppress the development and activation of autoreactive cells. Finally, we highlight how the modulation of CB1R and CB2R is advantageous in the treatment of autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM) and rheumatoid arthritis (RA). | |||